Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Licartin and/or ADV-TK after liver transplantation for prevention of hepatocellular carcinoma recurrence
ChiCTR-TRC-09000387Phase 4Completed
- Sponsor
- Air Force Medical University
- Start
- May 2009
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of licofelone, aglatimagene besadenovec and ganciclovir in hepatocellular carcinoma (HCC) (4 arms), sponsored by Air Force Medical University. Primary endpoints: Recurrence-free survival time or progression-free survival, Overall survival time and 2 more. Started May 2009; status: completed.
02
Drugs
licofeloneaglatimagene besadenovecganciclovir
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TRC-09000387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-09000387.